Amylin Pharmaceuticals Inc. (AMLN)

[mlkrborn]

AMLN: Down $10 to $10.
By Val Brickates Kennedy

NVO AMLN ALKS LLY

BOSTON (MarketWatch) -- Shares of Danish drug maker Novo Nordisk A/S /quotes/comstock/13*!nvo/quotes/nls/nvo (NVO 100.51, +9.52, +10.46%) jumped 10% in premarket trading Wednesday, the day after U.S. regulators declined to approve a hotly-anticipated diabetes medication called Bydureon that posed a competitive threat to Novo's diabetes drug franchise. Novo shares had been trading substantially lower recently in anticipation of a U.S. approval for the product. Bydureon was co-developed by Amylin Pharmaceuticals /quotes/comstock/15*!amln/quotes/nls/amln (AMLN 10.12, -10.37, -50.61%) , Alkermes Inc. /quotes/comstock/15*!alks/quotes/nls/alks (ALKS 10.35, -4.15, -28.62%) and Eli Lilly & Co. /quotes/comstock/13*!lly/quotes/nls/lly (LLY 35.62, -1.83, -4.89%) .